Doctors treating lymphoma patients with the CAR-T therapy Yescarta in the “real world” are seeing results that are slightly worse than data collected in the pivotal clinical trial conducted by Kite Pharma, now a part of Gilead Sciences. But the analysis may have been affected by the inclusion of sicker patients who would have been...